30 closest matches · ranked by relevance
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Triple Negative Breast Cancer
Primary: Number of Participants With Pathologic Response by HR-deficiency (HRD) Status — 9; 2; 10; 4 Participants
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 18 percentage of participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Triple Negative Locally Advanced Non-resectable Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) — 30.0; 35.9 percentage of participants
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Tumor · Breast Cancer
Primary: Objective Response Rate (ORR) — 28.6; 35 percentage of subjects
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Breast Neoplasms
Primary: Pathologic Complete Response (pCR) — 25 Participants
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Breast Cancer
Primary: Pathologic Complete Response — 23 Participants
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg